Bank of Nova Scotia acquired a new position in shares of AstraZeneca PLC (NASDAQ:AZN – Get Rating) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 5,361 shares of the company’s stock, valued at approximately $355,000.
A number of other hedge funds have also recently made changes to their positions in AZN. Arrowstreet Capital Limited Partnership boosted its position in shares of AstraZeneca by 407.1% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 4,093,345 shares of the company’s stock worth $271,553,000 after purchasing an additional 3,286,137 shares during the period. 1832 Asset Management L.P. boosted its position in AstraZeneca by 239.6% in the 1st quarter. 1832 Asset Management L.P. now owns 3,033,929 shares of the company’s stock valued at $198,533,000 after buying an additional 2,140,670 shares during the period. Farallon Capital Management LLC boosted its position in AstraZeneca by 87.6% in the 1st quarter. Farallon Capital Management LLC now owns 3,576,184 shares of the company’s stock valued at $237,244,000 after buying an additional 1,670,029 shares during the period. Capital International Investors boosted its position in AstraZeneca by 4.5% in the 1st quarter. Capital International Investors now owns 36,993,664 shares of the company’s stock valued at $2,458,428,000 after buying an additional 1,604,875 shares during the period. Finally, Ensign Peak Advisors Inc boosted its position in AstraZeneca by 179.9% in the 1st quarter. Ensign Peak Advisors Inc now owns 2,398,337 shares of the company’s stock valued at $159,106,000 after buying an additional 1,541,513 shares during the period. Hedge funds and other institutional investors own 21.55% of the company’s stock.
AstraZeneca Price Performance
Shares of NASDAQ:AZN opened at $65.07 on Monday. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.81 and a quick ratio of 0.67. The firm has a market capitalization of $201.64 billion, a P/E ratio of 97.12, a P/E/G ratio of 1.32 and a beta of 0.50. AstraZeneca PLC has a 12 month low of $52.65 and a 12 month high of $71.70. The company’s fifty day moving average price is $57.76 and its 200 day moving average price is $62.02.
Analyst Ratings Changes
AstraZeneca Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
- Get a free copy of the StockNews.com research report on AstraZeneca (AZN)
- Is GameStop Stock Setting Up for Another Short Squeeze?
- Here’s Why SoFi Technologies Stock is Cheap at These Levels
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.